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Volume 52, Number 3 Abstracts 80723 mm (OR, 2.96; 95% CI, 1.74-5.03), and a proximal neck length 22
mm (OR, 2.41; 95% CI, 1.42-4.10).
Conclusion: In this series, TSR was accurately predictive of a
durable success after EVAR. It occurred mostly in patients with a
favorable anatomy. Less intensive follow-up work-up seems to be safe in
patients with TSR.
Synchronous and Metachronous Thoracic Aneurysms (TAA) in Pa-
tients With Abdominal Aortic Aneurysms (AAA)
Rabih A. Chaer, MD, Rogerio Vasconcelos, MD, Jae Cho, MD, Robert
Rhee, MD, Luke Marone, MD, and Michel Makaroun, MD, UPMC,
Pittsburgh, Pa
Objectives: Although the association of TAA with AAA is known, the
exact incidence has not been described. Our goal was to quantify the
incidence of TAA in patients with an AAA and assess predictive factors for its
diagnosis.
Methods: This was a retrospective review of patients with AAA from
2000-2008. Univariate and logistic regression analyses of TAA predictors
were performed.
Results: We reviewed 2196 patients with an AAA, of which 1082
(49%) had a chest CT during follow-up. TAA was synchronous in 117
patients (10.8%) and metachronous in 136 (12.6%). Mean time to
diagnosis was 2.3 years. Mean diameter was 4.74 1.43 cm for AAA and
4.70  1.03 for TAA. Indications for the chest CT were variable. Most
common were AAA (15%), pulmonary embolus (14%), and lung cancer
(11%). Only 38% of AAAs and 14% of TAAs were repaired during the
study period. At a mean follow-up of 43.6 months, there were 79 deaths
(7%): 7 were AAA-related, and 13 died of TAA ruptures. Univariate
associations of AAA and TAA are described in the Table. Predictors of
TAA diagnosis by logistic regression include black race (OR, 1.8; P 
.02), family history of TAA (OR, 7.6; P  .04), hypertension (OR, 1.7;
P  .006), and obesity (OR, 1.7; P  .006). Diabetes, infrarenal AAA
location, and smoking have a negative association.
Conclusions: TAAs are quite common in patients with AAA. Routine
or targeted screening with a chest CT at the time of AAA diagnosis may be
indicated.
Type I Endoleak: Impact of Graft Selection and Anatomic Factors
Muhammad A. Khan,MD, Rajeev Dayal, MD, Sikandar Z. Khan,MD, Gray
Roberge, Peter Connelly, MD, and James F. McKinsey, MD, NewYork-
Presbyterian Hospital, New York, NY
Objectives: This study aimed to assess the impact of anatomic and
aortic endovascular graft characteristics on the occurrence of type 1 endoleak
after endovascular abdominal aortic aneurysm repair (EVAR).
Methods: A prospective database encompassing all patients treated
with EVAR between 2001 and 2009 was established and categorized based
on presence of endoleak. All patients were followed-up clinically and with
duplex imaging or CTA at 1, 6, and 12 months and yearly thereafter.
Preoperative anatomic and clinical variables were correlated with presence of
endoleak. Statistical analysis was performed using the independent-sample t
test and 2 tests as appropriate.Results: A total of 388 patients (75% male) with a mean age of 76.5
years (range, 42-96 years) underwent EVAR. Of these, 28 (7.2%) were
identified with postoperative type I endoleak (22 type Ia, 4 type Ib, and 2
combined Ia, Ib). The mean follow-up was 29 months (range, 1-98
months). Mean time to the detection of endoleak was 11.6 1.2 months
(range, 1-45 months). Two groups (type I endoleak vs no endoleak) were
similar regarding demographics and comorbidities, except for significantly
higher mean age, higher PVD, and lower smoking history in the type I
endoleak group. Primary factors associated with type I endoleak were
aneurysm size 63 mm (P  .001), age 80 (P  .027), shorter neck
length 15 mm (P  .005), reverse funnel neck configuration, infrarenal
stent fixation 14.6 mm (P  .006), and short distal iliac fixation (¾ of
common iliac length; P .05). Freedom from type I endoleak by graft type
was Zenith, 97.3%; Talent, 84.6%; Excluder, 100%; and AneuRx, 89%.Mean
aneurysm rupture-free period was 27.95 16months. Twenty-four patients
(86%) with type I endoleak underwent initial EVAR to seal the leak, with
83.4% success rate. Four patients (14%) required more than one reinterven-
tion to fix the endoleak. Seven patients (25%) required explant and conver-
sion to open repair. Overall mortality in type I endoleak group was 10.7% (3
of 28 all secondary to rupture).
Conclusion: The etiology of type I endoleak is multifactorial and
careful patient and graft selection is critical to reduce this potentially lethal
complication.
Anatomic predictors of type I endoleak
Variable No endoleak Type I endoleak P
Age 76.5  8.16 80  6.67 .027a
Max AAA diameter, mm 56.4  11.13 63.84  12.2 .001a
Prox neck diameter, mm 26.39  13.6 26.2  4.03 .951a
Neck length, mm 27.3  24 14.4  9.0 .005a
Neck configuration
(reverse funnel), No.
(%)
116 (32.3) 22 (78.6) .001b
Infrarenal stent fix, mm 27.8  24.8 14.6  9.0 .006a
Suprarenal stent fix, mm 13.6  8.1 10.6  6.8 .104a
Right iliac fixation, % 81.0 71.2 .007a
Left iliac fixation, % 81.1 71.5 .013a
aIndependent-sample t test; b2.
Outcome of Elective Endovascular Abdominal Aortic AneurysmRepair
in Nonagenarians
Stuart B. Prenner, BS, Irene C. Turnbull, MD, Gregory W. Serrao, BS,
Maggie Walkup, MD, Eric Fishman, MD, Sharif H. Ellozy, MD, Ageliki G.
Vouyouka, MD, Michael L. Marin, MD, and Peter L. Faries, MD, Mount
Sinai School of Medicine, New York, NY
Objective: Compared with open repair of abdominal aortic aneurysms
(AAA), endovascular repair (EVAR) is associated with decreased periopera-
tive morbidity and mortality in a standard patient population. This study
sought to determine if the advantage of EVAR extends to patients aged90
years.
Methods: This was a retrospective review from a prospectively main-
tained computerized database. Of the 1270 patients treated with EVAR
from January 1997 toNovember 2007, 24 (1.9%) were aged90.Mean age
was 91.5  1.5 years (range, 90-95 years), and 83.3% were male. Mean
aneurysm size was 6.8 cm (range, 5.2-8.7 cm; Table).
Results: Mean procedural blood loss was 490 mL (range, 100-4150
mL), and 20.8% required an intraoperative transfusion. Mean postoperative
length of stay was 6.0 days, (median, 4 days; mode, 1 day; range, 1-42 days),
with 33.3% of patients discharged on the first postoperative day. There were
six (25.0%) perioperative major adverse events and a perioperative mortality
rate of 8.3% (2 of 24). Mean follow-up was 20.5 months (range, 1-49
months). Overall, three patients (12.5%) required secondary intervention
(thrombectomy, angioplasty, and proximal cuff extension). No patients
required conversion to open repair, and two patients (8.3%) died of AAA
rupture at 42 and 517 days after EVAR. Freedom from all-cause mortality at
1 year was 80.9%. Freedom from aneurysm-related mortality at 5 years was
69.5% (Fig). Endoleak occurred in 6 patients (25.0%), with 3 type I, 1 type
II, and 2 of indeterminate type; of these, 2 patients with type I endoleak
underwent secondary intervention (153 and 489 days after EVAR), of which
one case was successful.
Conclusion: Our study supports that EVAR in nonagenarians is asso-
ciated with high procedural success and acceptable perioperative morbidity
and mortality. The midterm results support the use of EVAR in carefully
selected patients  90 years old.
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Total N  24
Hypertension 58.30%
Coronary artery disease 33.30%
Arrhythmia 37.50%
Myocardial infarction 20.80%
Congestive heart failure 12.50%
COPD 25.00%
Hyperlipidemia 25.00%
Creatinine 1.5 mg/dL 25.00%
Peripheral vascular disease 4.20%
Diabetes 8.30%
Stroke 4.20%
Smoking 54.20%
Cancer 8.30%
ASA class II 83.30%
ASA class III 16.70%
Scientific Session IV
Outcome of Carotid Artery Interventions Among Female Patients in
the United States, 2004-2005
Caron B. Rockman, Glenn R. Jacobowitz, MD, Jeffrey S. Berger, MD, Neal
S. Cayne, MD, Mark A. Adelman, MD, and Thomas S. Maldonado, MD,
New York University Medical Center, New York, NY
Objectives: The benefit of carotid endarterectomy (CEA) in women
has been questioned, particularly in asymptomatic cases, and an increased in
perioperative stroke in women after CEA has been noted. The outcome of
carotid artery angioplasty and stenting (CAS) has not been extensively
evaluated in women. Our objective was to examine the national outcome of
CEA and CAS in female patients.
Methods: The Nationwide Inpatient Sample and ICD-9 codes were
used to identify CEA and CAS cases performed in 2004 and 2005. Out-
comes included perioperative stroke and death. Comparisons were per-
formed between genders. Analysis was performed among female patients to
see whether outcomes differed based on the procedure used.
Results: Analysis included 54,658 cases; 94.2% CEA and 5.8% CAS.
Women comprised 42.3% of the cases. Women and men were equally likely
to be symptomatic (5.3% vs 5.3%, P  .8). Women were significantly less
likely to undergo CAS than men (5.4% vs 6.1%, P .001). Women and men
had similar rates of perioperative stoke when undergoing CEA (1.0% vs
1.0%, P  .9) and CAS (2.7% vs 2.0%, P  .2). However, symptomatic
women had a significantly higher rate of perioperative stroke overall than did
symptomatic men (3.8% vs 2.3%, P .3). Among female patients alone, the
perioperative stroke rate for asymptomatic womenwas significantly lower for
CEA than for CAS (0.9% vs 2.1%, P  .001); likewise, among symptomatic
women, the perioperative stroke rate favored CEA rather than CAS (3.4% vs
6.2%, P  .01).
Conclusions: National data reveal that fear of a high stroke rate after
CEA among asymptomatic women is unfounded. The overall stroke rate
among symptomatic women was higher than for symptomatic men, but still
acceptable for carotid intervention in symptomatic patients. Nationally,women underwent CAS less frequently than men. Outcome among women
with regard to perioperative stroke favored CEA over CAS, particularly in
asymptomatic cases. It appears that CEA may be the preferred treatment in
women who warrant intervention, unless compelling reasons exist to per-
form CAS.
Impact of Elevated Fasting Blood Glucose on the Outcomes of Carotid
Artery Stenting
Mark G. Davies, MD PhD, Jean Bismuth, MD, Joseph Naoum, MD,
Hosam ElSayed,MD,HeithamHussein, MD, Eric K. Peden,MD, and Alan
B. Lumsden, MD, Methodist Debakey Heart and Vascular Center, Hous-
ton, Tex
Background: Carotid artery stenting (CAS) for high-risk individuals is
accepted practice. An elevated fasting blood sugar (FBS) is often associated
with poor procedural outcomes after other percutaneous procedures. The
clinical outcomes of CAS for patients with elevated FBS is not well defined.
Methods:A database of patients undergoing carotid artery stenosis was
sampled from 2000 to 2009. An elevated FBS was defined as110 mg/dL.
Life-table analyses were performed to assess time-dependent outcome dif-
ferences between those patients with and without elevated FBS. The out-
comes of freedom from restenosis, occlusion, death, recurrent symptoms,
and neurologic event were calculated. Cox proportional hazard analysis or
the Fisher exact test was performed to identify factors associated with
outcomes. Data are presented as SD, unless otherwise indicated.
Results: During the study period 322 patients (196 men, 61.%)
underwent 345 CAS procedures. The mean follow-up was 4.6 years. The
indications for CAS were neurologic symptoms in high-risk patients in 23%
and asymptomatic high risk in the remainder. FBS was elevated in 59%, but
only 30% had a history of diabetes mellitus (DM). There was no difference in
the comorbidities between the elevated and normal FBS groups. Patients
with an elevated FBS were more likely to suffer a major adverse outcome of
death,MI, stroke, or TIA (26% vs 12%, P.001 by 2 analysis) in the 90-day
perioperative period. By Kaplan-Meier analysis, there were no differences
between normal FBS and elevated FBS patients for freedom from occlusion,
recurrent symptoms, neurologic event, and death. Patients carrying the
diagnosis of DM had equivalent outcomes to non-DM patients. No factor
contributed to the outcomes identified with an elevated FBS.
Conclusions: Patients with elevated FBS undergoing CAS are at a
greater risk for periprocedural morbidity and mortality. The diagnosis of
DM does not have a similar impact on outcomes. A current elevated FBS, as
opposed to a history of DM, should be considered an important risk factor
when determining the suitability for CAS.
Early Results of Stents Placed at the Origin of the Great Vessels: Does
Indication Influence Outcome
John B. Taggert, MD, Manish Mehta, MD, MPH, Sean P. Roddy, MD,
Yaron Sternbach, MD, Paul B. Kreienberg, MD, Philip S. K. Paty, MD,
Kathleen J. Ozsvath, MD, Benjamin B. Chang, MD, and R. Clement
Darling III,MD, AlbanyMedical College/AlbanyMedical CenterHospital,
Albany, NY
Purpose: Indications for balloon-expandable stent (BES) placement in
the great vessels include occlusive atherosclerotic disease as well as vessel
origin protection when thoracic endografts are placed with overlap of the
vessel origin.We compared early outcomes of in-stent restenosis in these two
groups of patients: those being treated for occlusive disease and those treated
as an adjunct to TEVAR.
Methods: From 2003 to 2008, 35 BESs were placed in the proximal
great vessels. Of these, 23 (65%) were placed for an occlusive indication.
When stents were placed in the innominate or common carotid artery, direct
exposure of the vessel in the neck was obtained with clamping of the vessel
distally during angioplasty/stenting to protect from embolization. Subcla-
vian lesions were accessed from the ipsilateral brachial artery. Twelve patients
(35%) underwent BES in association with TEVAR. None of these patients
had significant occlusive disease. Stents in the TEVAR group were placed at
the initial procedure as an adjunct to protect the great vessel origin from
endograft overlap. After the procedure, patients were typically treated with
life-long aspirin and a minimum of 4 weeks of Plavix.
Results: A total of 6 (17%) significant in-stent stenotic lesions have
occurred, all in patients treated for an atherosclerotic occlusive indication.
No episodes of in-stent stenosis have been observed when stents were placed
as an adjunct to TEVAR. The mean follow-up time is 18 months.
Conclusion: Restenosis rates of great vessels origin stents are lower
when placed as an adjunct to TEVAR than for occlusive indications. Exten-
sive calcification of the arch vessels appears to be a risk factor for restenosis.
